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Abstract: Three quantitative structure-activity relationship (QSAR) models for predicting the affinity
of mu-opioid receptor (µOR) ligands have been developed. The resulted models, exploiting the
accessibility of the QSAR modeling, generate a useful tool for the investigation and identification of
unclassified fentanyl-like structures. The models have been built using a set of 115 molecules using
Forge as a software, and the quality was confirmed by statistical analysis, resulting in being effective
for their predictive and descriptive capabilities. The three different approaches were then combined to
produce a consensus model and were exploited to explore the chemical landscape of 3000 fentanyl-like
structures, generated by a theoretical scaffold-hopping approach. The findings of this study should
facilitate the identification and classification of new µOR ligands with fentanyl-like structures.
Keywords: QSAR; fentanyl; µOR; opioid binding affinity; designer fentanyl-like molecules;
novel synthetic opioids; new psychoactive substances
1. Introduction
Opioid receptors are the target proteins of narcotic analgesics, of which morphine is the prototype,
and their activation can produce a variety of pharmacological responses [1] that are used for the
treatment of different medical conditions [2–4]. Their pharmacological action had been known long
before the morphine itself was discovered, and, in early civilizations, extracts from the Papaver
somniferum were widely used as a medicine [5]. Unfortunately, even at that period, the poppy plant
was used as a recreational agent, and this social plague is still present all over the world representing a
severe problem to societies [5]. The agents most commonly responsible for the increase in the number
of drug overdose-related deaths are synthetic opioids and heroin [6]. In fact, opioid-related overdose
deaths due to synthetic opioids are rapidly increasing, augmenting an already established plague to
society [7,8]. The low cost, affordable synthetic procedures, and the high potency have led to the influx
of fentanyl analogs into the street-drug market as indicated by the Drug Enforcement Administration
(DEA) [9]. A significant additional risk to public health is the variability in potency among fentanyl
analogs; indeed, certain derivatives (e.g., carfentanyl) are 10,000 times more potent than morphine [10],
resulting in a potentially fatal dose for drug-addicted persons. Fentanyl is a potent agonist of the
µOR, causing the classical analgesic and euphoric pharmacological effects of this class of compounds.
Unfortunately, simple modifications of the central core of the molecule (4-anilidopiperidine, Figure 1)
may produce ligands with increased potency, resulting in a high risk for the user. Importantly, many
structural modifications to the original fentanyl chemical scaffold do not alter the primary function
and binding properties to the µOR, resulting in a very large chemical space of fentanyl analogs with
abuse potential.
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Figure 1. Structure of fentanyl and fentanyl-like co pounds.
In the USA, the DEA can schedule a substance to a legislative state regarding its physiological
abuse potential; however, a complete analysis to support scheduling can take up to two years. For this
reason, the Center for Drug Evaluation and Research has recently developed a docking-based virtual
screening approach for the identification and hazard characterization of unclassified fentanyl-like
structures [11]. Surprisingly, a ligand-based method for the classification of designer fentanyl-like
structures has never been evaluated.
Quantitative structure-activity relationship (QSAR) models models are frequently used to facilitate
the prediction and comprehension of patterns in the chemical and biological sciences [12–18]. In order
to facilitate the investigation of unclassified fentanyl-like structures, exploiting QSAR methodology,
we report the development of three different QSAR models established using a set of 115 fentanyl-like
structures. The generated models, employed to evaluate a set of new potentially µOR binders,
have been suggested employing the activity cliff analysis followed by a scaffold hopping study.
2. Results and Discussion
2.1. Statistical Analysis and Results
For the calculation of the different models, Forge uses the SIMPLS algorithm [19,20]. All the
experimental vs. predicted activities for the training and the test sets of the different models are
presented in Figure 2. The optimal number of components in partial least squares (PLS) analysis was
10-, 2- and 3-component for the field-based 3D-model, and the FCFP6 and ECFP6 circular fingerprint
descriptor 2D-models, respectively (Figures S1–S6). All of the generated models showed both good
predictive and descriptive capabilities, demonstrated by the high r2 and q2 values for both the training
and the cross-validated training sets (Table 1). The plots of experimental vs. predicted affinities for
the molecules included in the test set (Figure 2) show a reasonable prediction demonstrated by the
cross-validated r2 (Table 1). Among the three different models, the presence of the 3D-descriptors
included in the 3D-field model clearly increased the quality of the description, as demonstrated by the
high value of r2 (0.99) for the training set. Furthermore, the predictive capabilities resulted from such
model are the best across the three models (r2 for the test set = 0.77, Tables S1 and S2). The results of
the r2 test set >q2 have been referred to as the Kubinyi paradox and derive from the cross-validation
method (leave-one-out) [21]. The reliability of the models was also evaluated by the measurement
of the forecast errors. The mean squared error (MSE), the mean absolute error (MAE) and the mean
absolute percentage error (MAPE) for the three models are reported in Table 1, all of them confirmed
the statistical reliability of the obtained models.
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Model r
2 Training
Set
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Set
MSE a
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MAE b
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MAE b
Test Set
MAPE c
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MAPE c
Test Set
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The 3D visualizations, employing activity-atlas (AA), of the QSAR models superposed with the
structure of fentanyl are shown in Figure 3. The conclusion of this visualization highlight that the
3D-field model is described by steric and electrostatic effects. The four colors on the 3D-map represent
the different electrostatic (red and blue), and hydrophobic and shape features (green and violet).
In the green areas, a bulk/hydrophobic interaction improves the binding affinity; opposite results are
observed within the violet areas, where a bulk/hydrophobic interaction decreases the affinity. In the
red areas, a more positive electrostatic field increases the receptor-affinity, whereas in the blue regions
a more negative electrostatic field increases the affinity. From this representation, it appears that the
bulk/hydrophobic interactions have a more relevant impact on the activity of the molecules; indeed,
a green area is shown near to the R2 group of the fentanyl (Figure 1). This area is the hydrophobic
pocket formed by Ile 144, Leu 200 and Tyr 148 of the µOR. Potent opioid analogs can be derived by
simple substitution around this chemical space [22]. Moreover, another green area is located where
R3-substituents are usually accommodated, further indicating that the presence of a fragment moiety
in this area will produce potent fentanyl-like analogs. Two additional green areas are located near the
two aromatic rings. The aromatic ring linked to the R5 is located in an area near to Tyr 326, whereas
the other one in a pocket formed by Trp 19 and Tyr 148; both interact by pi–pi interactions with the
indicated residues [22]. A red area is located near the positively charged amine in the fentanyl structure,
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indicative of the presence of a negatively charged amino acid (Asp 147) in this region which can interact
with the ligand group by a salt-bridge. The blue area near the fentanyl’s carbonyl group indicates a
region able to interact with one of the oxygen atoms, presumably represented by the His 297.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 4 of 11 
 
in the fentanyl structure, indicative of the presence of a negatively charged amino acid (Asp 147) in 
this region which can interact with the ligand group by a salt-bridge. The blue area near the fentanyl’s 
carbonyl group indicates a region able to interact with one of the oxygen atoms, presumably 
represented by the His 297. 
 
Figure 3. The AA model map is superimposed to fentanyl. Molecular insight of structure-activity 
relationship (SAR) mechanism models, revealing the different lead optimization sites of active 
compounds. Red color shows positive field region controlling the activity, and blue color the negative 
ones. Green color shows favorable shape/hydrophobic regions, and violet color the unfavorable ones. 
2.2. Activity Cliffs in the Activity Landscape of the QSAR Set 
Usually, the activity cliff definition is strictly related to the activity landscape concept. An 
activity landscape is usually considered as a hypersurface where potency/activity of a particular 
compound is added as a third dimension to a 2D projection of the chemical space. In this concept, 
discontinuous SARs are regions termed as activity cliffs, which are formed by pairs of structurally 
similar compounds with large differences in potency. In these areas, the similarity hypothesis 
(structurally similar compounds will have similar biological activities) breaks down, and these areas 
are the most useful regions of the activity landscape for a compound series, gaining an improved 
understanding of interactions with the target protein. To facilitate this task, a methodology known 
as activity miner (AM) has been applied to the presented dataset of fentanyl-like compounds [23]. This 
methodology is based on the same XED/FieldAlign technology used for the development of the 
QSAR model. Specifically, a 3D-similarity metric was used, taking advantage of the same alignment 
produced for the development of the 3D-QSAR model, which was the best performing platform for 
predictive and descriptive capabilities. Fundamental to the application of the AM calculation is the 
concept of disparity, defined as the difference between the activities of two molecules divided by the 
distance (similarity) between them. High disparity values are obtained when the similarity is high, 
and the difference in activity is large—i.e., a small change in the molecule has made a substantial 
change in the activity. The seven activity cliffs with the highest values of disparity founded with the 
AM approach are reported in Table 2. From this analysis, it is clear that the presence of a substituent 
on the R3 (Figure 1) is fundamental for a high activity, and the presence of a simple hydrogen atom 
drops down the potency (Table 2, entries 3, 5, and 7). Moreover, an alkyl chain with more than two 
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Figure 3. The AA model map is superimposed to fentanyl. Molecular insight of structure-activity
relationship (SAR) mechanism models, revealing the different lead optimization sites of active
compounds. Red color shows positive field region controlling the activity, and blue color the negative
ones. Green color shows favorable shape/hydrophobic regions, and violet color the unfavorable ones.
2.2. Activity Cliffs in the Activity Landscape of the QSAR Set
Usually, the activity cliff definition is strictly related to the activity landscape concept. An activity
landscape is usually considered as a hypersurface where potency/activity of a particular compound is
added as a third dimension to a 2D projection of the chemical space. In this concept, discontinuous SARs
are regions termed as activity cliffs, which are formed by pairs of structurally similar compounds with
large differences in potency. In these areas, the similarity hypothesis (structurally similar compounds
will have similar biological activities) breaks down, and these areas are the most useful regions of
the activity landscape for a compound series, gaining an improved understanding of interactions
with the target protein. To facilitate this task, a methodology known as activity miner (AM) has been
applied to the presented dataset of fentanyl-like compounds [23]. This methodology is based on
the same XED/FieldAlign technology used for the development of the QSAR model. Specifically, a
3D-similarity metric was used, taking advantage of the same alignment produced for the development
of the 3D-QSAR model, which was the best performing platform for predictive and descriptive
capabilities. Fundamental to the application of the AM calculation is the concept of disparity, defined
as the difference between the activities of two molecules divided by the distance (similarity) between
them. High disparity values are obtained when the similarity is high, and the difference in activity is
large—i.e., a small change in the molecule has made a substantial change in the activity. The seven
activity cliffs with the highest values of disparity founded with the AM approach are reported in Table 2.
From this analysis, it is clear that the presence of a substituent on the R3 (Figure 1) is fundamental
for a high activity, and the presence of a simple hydrogen atom drops down the potency (Table 2,
entries 3, 5, and 7). Moreover, an alkyl chain with more than two atoms will produce less potent
analogs (Table 2, entries 1–3). The presence of a different aromatic substituent in R5 is tolerated (Table 2,
entry 5), whereas its removal produces less active compounds (Table 2, entries 6 and 7). The results of
the activity cliffs analysis suggest to further investigate the activity landscape inherent to suitable R3
and R5 substitutions.
Int. J. Mol. Sci. 2019, 20, 2311 5 of 10
Table 2. Activity cliffs resulted from the AM approach.
Entry Structure and pKi of theMost Active Analogs
Structure and pKi of the Less
Active Analogs Disparity ∆ Activity
1
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2.3. Enlarging the Activity Landscape of Fentanyl-like Compounds
In order to enlar the chemic l landscape evaluati n of fentanyl-like compounds, a bioisosteric
and fragment replacement software tool (Spark v10.4.0, Cresset, New Cambridge House, Hertfordshire,
United Kingdom) was adopted to produc a scaffold-ho pi g analysis and to generate a virtual library
of µOR ligands [24,25], investigating not only the appropriate replacement of the R3 and R5 substituents,
as suggested by the AM analysis, but also the decoration of other selected portions present in the
original structure of fentanyl (Figure 4, R1, R2, and R4 substituents). In particular, the molecule was
divided into six different parts to produces as much series (Figure 4), and 500 new virtual molecules
were generated for each substitution pattern for a total of 3000 analogs (see Supplementary material,
Tables S3–S8). Subsequently, each ligand was evaluated by exploiting the predictive capabilities of
the 3D-field and 2D-kNN QSAR models. For each case, the replacement was performed using the
same dataset of fragments already reported by us [26]. The top-scored compounds, according to
the median of the three models (3D-field, 2D-ECFP6 and 2D-FCFP6), and considering only values
within the domain of applicability of each model, are reported in Table 3. The results outline that the
Int. J. Mol. Sci. 2019, 20, 2311 6 of 10
replacement generated new structures with optimized chemical features for the binding to the µOR.
The results of all the series demonstrate that the chemical landscape for this class of compounds is
still huge and small modifications may further increase the activity of the parent molecule. Series 1–3
produced compounds with relatively low predicted affinities, possessing pKi ≤ 9, demonstrating that,
potentially, any substituent in these regions should not produce powerful and potentially harmful
compounds. This suggests that the activity landscape around this area can be exploited to prepare only
novel fentanyl-like compounds with reduced potency. Conversely, the results obtained from Series 4–6
confirmed again that the R3 position (Figure 1) is the one that mostly affects the affinity increase,
and that exploring the chemical space around this area, even using a cyclic system as suggested by our
results, would typically produce highly potent ligands. While this data could be used advantageously
for producing more effective radiotracers or to placate animals [27], these findings are a double-edged
sword, and serious risks for human health must be taken into account.
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2.4. Designer Drugs from the Scaffold-Hopping Results 
Newly-identified fentanyl analogs often lack any in vitro and/or in vivo pharmacology data. 
Some of the identified molecules are temporarily placed by the DEA in the US Schedule I waiting for 
complete analyses and data, which can be a time-consuming exercise. Virtual screening may 
represent a valid and faster alternative, and it was already reported that structure-based methods 
might allow speeding-up the identification and classification of potentially toxic compounds [11]. To 
further validate the predicting capabilities of our consensus QSAR ligand-based approach, we 
decided to investigate previously reported designer drugs—also known as Novel Psychoactive 
Substances (NPS)—among the results of the scaffold hopping approach. Interestingly, a number of 
already reported designer fentanyl-like compounds were found, including furanylfentanyl, 
acetylfentanyl, acrylfentanyl, benzodioxolefentanyl, cyclopentylfentanyl, 
tetramethylcyclopropylfentanyl, tetrahydrofuranylfentanyl, 3-furanylfentanyl, a-methylfentanyl, 
acryloylfentanyl, cyclopropylfentanyl, 4-fluorofentanyl, methoxyacetylfentanyl, 3-methylfentanyl, 4-
fluoroisobutyrylfentanyl, 4-chlorisobutyrfentanyl, 4-methoxybutyrfentanyl, β-hydroxythiofentanyl 
and isobutyrylfentanyl, predicted to have pKi of 8.5, 8.3, 8.5, 8.4, 8.3, 7.9, 8.2, 8.4, 8.7, 8.5, 8.6, 7.9, 8.1, 
8.5, 7.8, 8.0, 8.0, 8.1 and 8.6, respectively. All of these compounds are potent μOR ligands and some 
of them have already been attributed to a large number of fatalities worldwide [28,29]. All such NPS 
were identified as potent ligands by our methodology, strengthening the quality of our consensus 
methodology. 
3. Materials and Methods 
3.1. Biological Data 
The chemical structures of all the molecules were retrieved from the ChEMBL database selecting 
only those tested for their affinity for the human μOR (available online: 
https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL233). Datawarrior (5.0.0, Idorsia 
Pharmaceuticals Ltd., Allschwil, Switzerland) [30] was used for handling the selection of the 
molecules with fentanyl-like structures among the entire downloaded dataset. Only molecules where 
the displacement of the radioligand [3H]DAMGO from the human μOR was used for the 
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2.4. Designer Drugs from the Scaffold-Hopping Results
Newly-identified fentanyl analogs often lack any in vitro and/or in vivo pharmacology data. Some
of the identified molecules are temporarily placed by the DEA in the US Schedule I waiting for complete
analyses and data, which can be a time-consuming exercise. Virtual screening may represent a valid and
faster alternative, and it was already reported that structure-based methods might allow speeding-up the
identification and classification of potentially toxic compounds [11]. To further validate the predicting
capabilities of our consensus QSAR ligand-based approach, we decided to investigate previously
reported designer drugs—also known as Novel Psychoactive Substances (NPS)—among the results
of the scaffold hopping approach. Interestingly, a number of already reported designer fentanyl-like
compounds were found, including furanylfentanyl, acetylfentanyl, acrylfentanyl, benzodioxolefentanyl,
cyclopentylfentanyl, tetramethylcyclopropylfentanyl, tetrahydrofuranylfentanyl, 3-furanylfentanyl,
a-methylfentanyl, acryloylfentanyl, cyclopropylfentanyl, 4-fluorofentanyl, methoxyacetylfentanyl,
3-methylfentanyl, 4-fluoroisobutyrylfentanyl, 4-chlorisobutyrfentanyl, 4-methoxybutyrfentanyl,
β-hydroxythiofentanyl and isobutyrylfentanyl, predicted to have pKi of 8.5, 8.3, 8.5, 8.4, 8.3, 7.9,
8.2, 8.4, 8.7, 8.5, 8.6, 7.9, 8.1, 8.5, 7.8, 8.0, 8.0, 8.1 and 8.6, respectively. All of these compounds are
potent µOR ligands and some of them have already been attributed to a large number of fatalities
worldwide [28,29]. All such NPS were identified as potent ligands by our methodology, strengthening
the quality of our consensus methodology.
3. Materials and Methods
3.1. Biological Data
The chemical structures of all the molecules were retrieved from the ChEMBL database selecting
only those tested for their affinity for the human µOR (available online: https://www.ebi.ac.uk/
chembl/target/inspect/CHEMBL233). Datawarrior (5.0.0, Idorsia Pharmaceuticals Ltd., Allschwil,
Switzerland) [30] was used for handling the selection of the molecules with fentanyl-like structures
among the entire downloaded dataset. Only molecules where the displacement of the radioligand
[3H]DAMGO from the human µOR was used for the determination of all of the Ki values, were selected.
The binding affinity data were converted into their negative decimal logarithm pKi (pKi = −logKi).
3.2. Molecular Modeling
The two-dimensional structures of the dataset were built using Marvin Sketch (18.24, ChemAxon
Ltd., Budapest, Hungary). The protonation states of the molecules were calculated assuming a neutral
pH, and the Merck molecular force field (MMFF94) was used for a first 3D geometry optimization.
Subsequently, the geometry of the resulting 3D structures was optimized at a semi-empirical level
using the parameterized model number 3 (PM3) Hamiltonian as implemented in the MOPAC package
(MOPAC2016 v. 18.151, Stewart Computational Chemistry, Colorado Springs, CO, USA) [31,32].
3.3. Compound Alignment for the 3D Model and kNN Models Information
All the fentanyl-like 3D-optimized structures were imported into the software Forge
(v10.4.2, Cresset, New Cambridge House, Hertfordshire, UK) [23] to set the field-based 3D-QSAR
model and the 2D k-Nearest Neighbor (kNN) models. Out of the 115 structures, 94 molecules were
randomly selected as a training set while the remaining 21 were used as an external validation (test set)
to evaluate the models [33] (Tables S1 and S2). The molecules in the training set and the test set
covered a pKi range from 10.1 to 5.3. Ten different splits were tried and the results were consistent
to the reported ones. All the fentanyl-like molecules were aligned using fentanyl in its previously
reported conformation [22]. The field points (negative and positive electrostatic, van der Waals shape,
and hydrophobic description of the molecules) were generated using the extended electron distribution
(XED) force field included in Forge. All the software parameters used for the conformation hunt,
alignment, and model building calculations are presented in the Supplementary material (Figure S1–S6,
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Tables S1 and S2). As an alternative to the 3D-field QSAR, we also developed other two QSAR models
using the kNN method with the same software. The kNN approach is well-known, robust and has an
effective distance learning approach [34,35]. The two kNN models were developed using two different
2D-fingerprint similarities: the ECFP6 and the FCFP6 circular fingerprint descriptors. More detailed
information for the kNN models generations is reported in the Supplementary material.
4. Conclusions
The present study explores the development of three QSAR models exploitable for the prediction of
a ligand affinity to theµOR, and for the identification of new molecules that could efficiently interact with
such receptor class. Forge was employed to build a statistically robust QSAR evaluating methodology
using a set of 115 fentanyl-analogs covering a wide range of known µOR ligands. An activity cliff
analysis followed by a scaffold-hopping approach has been performed to provide a theoretical route for
the exploration of novel unidentified fentanyl-analogs with high potency. The QSAR models reported
here will guarantee, prospectively, fruitful applications to speed up the design and the identification
process of new µOR ligands with tunable activities. Since µOR fentanyl-like ligands currently represent
a well-explored class of synthetic opioids, often associated with fatal cases worldwide, this proposed
ligand-based tool could be considered by the DEA, the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA), and other regulatory bodies for speeding-up the classification of novel
fentanyl-like NPS. Likewise, the newly identified libraries may potentially aid the interpretation of
toxicological analyses where the presence of novel synthetic opioids is postulated.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/9/2311/s1.
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